Literature DB >> 26033845

Telemedicine in US Army soldiers with type 1 diabetes.

Y Sammy Choi1, Jon Cucura2, Ram Jain3, Cristobal Berry-Caban4.   

Abstract

A retrospective study of a telemedicine clinic for active duty US Army soldiers with type 1 diabetes was conducted. Fifty-one consecutive patients (mean age 33.9 years) were enrolled into the clinic. All soldiers with known or newly diagnosed type 1 diabetes received three weekly office visits for intensive diabetes education. After this, all communication occurred via a messaging system consisting of texting, web-based download, and/or email to a diabetes management team. For urgent matters, 24/7 direct paging or telephone access was provided. Routine adjustments in insulin dosing were accomplished via email. Soldiers were followed for a mean of 17.1 months. Baseline, three-month, and end of study glycated hemoglobin (A1C) values were 9.8, 7.3, and 6.9, respectively. There were no significant differences in end of study A1C levels between patients with known vs. newly diagnosed type 1 diabetes, nor were there any differences between those patients who received insulin via pump therapy vs. multiple daily injections. Telemedicine was safe and effective in lowering A1C levels in US Army soldiers with type 1 diabetes.
© The Author(s) 2015.

Entities:  

Keywords:  Type 1 diabetes; military; soldiers; telemedicine

Mesh:

Substances:

Year:  2015        PMID: 26033845     DOI: 10.1177/1357633X15583425

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  2 in total

1.  Rural Telehealth Visits in the Management of Type 1 Diabetes.

Authors:  Leslie A Eiland; Andjela Drincic
Journal:  J Diabetes Sci Technol       Date:  2021-10-12

Review 2.  Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model.

Authors:  Matthew F Bouchonville; Margaret M Paul; John Billings; Jessica B Kirk; Sanjeev Arora
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.